TCBP - Rasio utang marang kapitalisasi buku TC BioPharm (Holdings) Plc

The creation of a cellular immunity system based on gamma-delta T-cells allows TC Biopharm (TCBP) to combat infections and cancer without side effects. This financial leverage chart based on balance sheet capitalization demonstrates volatility, where the 0.88 level serves as a critical mark. Scalability is ensured through the use of donor cells for the mass production of drugs. Massive sales potential is unlocked through the development of acute leukemia therapy.

The stable geopolitical status of TC Biopharm (TCBP) within the Western circuit minimizes external risks to its biomedical developments. By analyzing the current debt-to-equity ratio, an investor assesses the company's reliance on borrowed funds relative to its own equity. This ratio measures financial stability and default risk amid interest rate fluctuations. An optimal balance prevents asset stagnation while ensuring the development of patents. Such parameters characterize the asset as a high-tech investment class.